Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.

医学 英夫利昔单抗 类风湿性关节炎 皮疹 不利影响 内科学 甲氨蝶呤 外科 安慰剂 痹症科 胃肠病学 关节炎 肿瘤坏死因子α 病理 替代医学
作者
T. Huizinga,St Clair Ew,McCune Wj,TAJ Braakman,Peter E. Lipsky
出处
期刊:PubMed 卷期号:27 (4): 841-50 被引量:119
链接
标识
摘要

To evaluate the safety and efficacy of single and multiple doses of a chimeric anti-TNF-alpha monoclonal antibody (infliximab) in patients with rheumatoid arthritis (RA) who had active disease despite therapy with methotrexate (MTX).Twenty-eight patients with active RA despite receiving therapy with 10 mg/week of MTX were randomized to receive a single, blinded infusion of either placebo or 5, 10, or 20 mg/kg infliximab. Twenty-three patients who completed the blinded study entered an open, multiple dose extension study in which they received up to 3 additional infusions of 10 mg/kg infliximab at Weeks 12, 20, and 28. Safety, efficacy, and pharmacokinetics were evaluated during the blinded and open trial.There were no serious infusion related reactions. In the blinded phase, 17 (81.0%) of 21 patients receiving infliximab achieved an American College of Rheumatology (ACR) 20% response at some point during the 12 weeks of followup compared to one (14.3%) of 7 patients receiving placebo (p = 0.003). Clinical improvement was evident by the first week and was sustained through Week 12. For the 19 patients who received infliximab during the blinded part of the trial and continued into the open label trial, 53% maintained an ACR 20% response with multiple infusions of 10 mg/kg infliximab through Week 40. Three patients withdrew from the trial during the open continuation phase because of adverse events: cellulitis, infusion related dizziness and headache, and vasculitic rash. Infliximab in doses of 5 to 20 mg/kg had a mean terminal half-life ranging from 9 to 12 days and was detectable in sera from most patients 8 to 12 weeks after dosing.Infliximab is generally well tolerated during 40 weeks of therapy. A single infusion of 5 to 20 mg/kg infliximab significantly decreases the signs and symptoms of RA compared to placebo in patients with active disease receiving MTX. Multiple doses of infliximab produce sustained clinical benefit for up to 40 weeks.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
九秋霜发布了新的文献求助10
1秒前
meng136281发布了新的文献求助10
1秒前
2秒前
樊珩完成签到,获得积分10
2秒前
3秒前
7秒前
小花花发布了新的文献求助20
10秒前
10秒前
SciGPT应助哈哈哈哈哈采纳,获得10
10秒前
liu发布了新的文献求助10
11秒前
笑笑丶不爱笑完成签到,获得积分10
11秒前
小王完成签到,获得积分10
11秒前
lily发布了新的文献求助10
12秒前
鱼鱼完成签到,获得积分10
12秒前
英姑应助meng136281采纳,获得10
13秒前
linlin完成签到,获得积分10
15秒前
科研通AI2S应助刻苦海豚采纳,获得10
15秒前
16秒前
17秒前
天天快乐应助fangfang采纳,获得10
18秒前
甜甜玫瑰应助liu采纳,获得10
18秒前
兴奋的觅露完成签到,获得积分10
21秒前
23秒前
赘婿应助jayus采纳,获得10
23秒前
Ava应助比奇堡悍匪派大星采纳,获得10
26秒前
27秒前
殷勤的紫槐完成签到,获得积分10
27秒前
饱满天磊应助小王采纳,获得50
29秒前
汉堡包应助泡沫没有冰采纳,获得10
29秒前
29秒前
哈哈哈哈哈完成签到,获得积分10
29秒前
stszd完成签到,获得积分10
30秒前
31秒前
小小完成签到 ,获得积分10
32秒前
搜集达人应助腼腆的立诚采纳,获得10
32秒前
王先生完成签到,获得积分10
33秒前
kk完成签到,获得积分10
33秒前
34秒前
小慧儿完成签到 ,获得积分10
36秒前
36秒前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3050909
求助须知:如何正确求助?哪些是违规求助? 2708236
关于积分的说明 7412010
捐赠科研通 2352411
什么是DOI,文献DOI怎么找? 1245174
科研通“疑难数据库(出版商)”最低求助积分说明 605463
版权声明 595796